Skip to main content Skip to navigation

[University home]

School of Medicine

Dr Lynne Hampson PhD. MIBMS

Photograph of Lynne Hampson

Non Clinical Lecturer in Gynaecological Oncology

Room L5.CT.380
Research
St Mary's Hospital
Oxford Road
Manchester
M13 9WL

 

Role

I currently help to lead a team of post-doctoral researchers and PhD students working on a variety of projects in the area of basic cancer research with the current main interest of the group being the role of viruses in the aetiology and pathogenesis of cancer. In addition I tutor and examine Portfolio to Phase 1 Medical Students and act as an Academic Tutor for the Manchester Access Programme.

I am actively involved in Health and Safety issues within the University and hold positions on several Committees including:

  • Cancer and Enabling Sciences H&S Committee (deputy Chair)
  • St Mary's Genetic Modification Committee (Chair)
  • University Biohazards Advisory Committee
  • Hospital Human Tissue Authority Person Designate

Co-Director of a University Spin-Out Biotech Company - ViBio

 

Memberships of Committees and Professional Bodies

Member of:

  • Institute of Biomedical Sciences
  • Manchester Prevention of Cancer Network
  • International Society for Infectious Diseases

Research

 Current Research Interests

  • The role of human viruses in cancer
  • Identification of new cancer diagnostic and prognostic markers
  • Development of novel cancer therapeutics
 

Methodological Knowledge

A wide variety of molecular and cellular biology techniques.

 

Teaching

  • Tutor and Examiner Medical Undergraduate Degree Programme (MB ChB) Phase 1 Portfolio
  • SSC Project Supervisor Medical Undergraduate Degree Programme Year 1
  • Academic Tutor manchester Access Programme
  • PhD and MRes supervisor
  • Undergraduate selection interviewer (MB ChB)
 

Qualifications

PhD in Medical Oncology from the University of Manchester. Also a qualified Medical Laboratory Scientific Officer (specialist area Clinical Haematology and Blood Group Serology).

 

Collaborators and affiliated staff

  • Dr Xiao-tong He - Post Doctoral Research Associate
  • Dr Anthony Oliver - Post Doctoral Research Associate
  • Dr Gavin Batmen - Post Doctoral Research Associate
  • Mr Paul Wilcock - PhD Student
  • Mr Rowaid Qahwaji - PhD Student
  • Mr Sultan Alqahtani - PhD Student
  • Miss Shaihana Alamtrrouk- PhD Student
  • Mr Bandar Alosaimi - PhD Student
  • Mr Fadi Qashqari - PhD Student
 

Publications

2011

  • 1. Ingeborg Zehbe1, Christina Richard, Kyle F. Lee, Michael Campbell, Lynne Hampson and Ian N. Hampson. (2011). Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus lesions. Anti Viral Research, eScholarID:125809 | DOI:10.1016/j.antiviral.2011.05.016
  • 4. Gavin Batman, Anthony W Oliver, Ingeborg Zehbe, Christina Richards, Lynne Hampson and Ian N. Hampson. (2011). The HIV protease inhibitor lopinavir up-regulates expression of the antiviral protein ribonuclease L in HPV positive cervical carcinoma cells. Antiviral Therapy, 16(4), 515-525. eScholarID:125808 | DOI:10.3851/IMP1786
  • 5. Oliver AW., He XT., Borthwicke K., Donne AJ., Hampson L* and Hampson IN. (2011). The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16 which activates Cdc42. British Journal of Cancer, 104(2), 324-331. eScholarID:123846 | DOI:10.1038/sj.bjc.6606026

2010

  • 6. Dong-Hyun Kim, Roger M. Jarvis, J. William Allwood, Gavin Batman, Rowan E. Moore, Emma Marsden-Edwards, Lynne Hampson*, Ian N. Hampson and Royston Goodacre. (2010). Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. Analytical and Bio-analytical Biochemistry, 398(7-8), 3051-3061. eScholarID:123848 | DOI:10.1007/s00216-010-4283-6
  • Dong-Hyun Kim, Roger M. Jarvis, Yun Xu, Anthony W. Oliver, J. William Allwood, Lynne Hampson, Ian N. Hampson and Royston Goodacre. (2010). Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst, eScholarID:80471 | DOI:10.1039/b923046g
  • Donne AJ, Hampson L, Homer JJ, Hampson IN. (2010). The role of HPV type in Recurrent Respiratory Papillomatosis. Int J Pediatr Otorhinolaryngol, 74, 7-14. eScholarID:35008 | DOI:10.1016/j.ijporl.2009.09.004
  • Shin, Hye-Jin; Kim, Joo-Young; Hampson, Lynne; Pyo, Hong Ryull; Baek, Hye Jung; Roberts, Stephen A; Hendry, Jolyon; Hampson, Ian N. (2010). Human Papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells, associated with up-regulation of aurora A. Radiation Biology, eScholarID:80472 | DOI:10.3109/09553002.2010.484477

2009

  • Donne A, Hampson L, He X, Rothera M, Homer JJ, Hampson IN. (2009). Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck, 31( 7), eScholarID:1d19659 | DOI:10.1002/hed.21043
  • Donne AJ., Hampson L., He XT., Day PJ., Salway F., Rothera MP., Homer JJ and Hampson IN. (2009). Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antiviral Therapy, 14(7), 939-952. eScholarID:80470 | DOI:10.3851/IMP1421
  • Hampson L, He XT, Oliver AW, Hadfield JA, Kemp T, Butler J, McGown A, Kitchener HC, Hampson IN. (2009). Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies. British Journal of Cancer, 101(5), 829-839. eScholarID:34978 | DOI:10.1038/sj.bjc.6605208

2007

  • Donne A, Hampson L, He X, Rothera MP, Homer JJ, Hampson IN. (2007). Effects of cidofovir on a novel cell based test system for recurrent respiratory papillomatosis. Head and neck - E-Pub ahead of print, In Press 2007, eScholarID:1d13088
  • Silva, P, West, CML, Slevin, NJ, Valentine, HR, Ryder, WDJ, Hampson, L, Bibi, R, Sloan, P, Thakker, NS, Homer, J, Hampson, IN. (2007). Tumor expression of major vault protein (MVP) is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Rad Oncol Biol Phys, 69, eScholarID:1d15644

2006

  • Hampson L, Kitchener HC, Hampson IN. (2006). Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6 dependent cervical carcinoma cells in vitro. Antiviral Therapy, 11 (6), 813-825. eScholarID:1d13089

2004

  • Hampson L, Li CS, Oliver AW, Kitchener HC, Hampson IN. (2004). The PDZ protein Tip-1 is a gain of function target of the HPV16 E6 oncoprotein. Int J. Oncol, 25(5):, 1249-56. eScholarID:1d10171
  • Xiaotong HE, Brenchley PEC, Jayson G-, Hampson L, Davies J, Hampson IN. (2004). Hypoxia increases heparanase dependent tumour cell invasion which can be inhibited by anti-heparanase antibodies. Cancer Research, eScholarID:1d26158

2003

  • Morris EC, Daffron TR, Forsyth SL, Missen MA, Horvath AJ, Hampson L, Hampson IN, Carrell RW, Coughlin PB. (2003). Murine Serpin 2A is a redox sensitive intracellular protein. Biochem J, 371 (1), 165-73. eScholarID:1d6377

2002

  • Hamerman JA, Hayashi F, schroeder LA, Gygi SP, Haas AL, Hampson L, Coughlin P, Aebersold R, Aderem A. (2002). Serpin 2a is induced in activated macrophages and conjugates to a ubiquitin homolog. J Immunol, 168(5), 2415-2423. eScholarID:1d3860

2001

  • Baird, JW, Ryan, KM, Hayes, I, Hampson, L, Heyworth, CM, Clark, A, Wooten, M, Ansell, JD, Menzel, U, Hole, N, Graham, GJ. (2001). Differentiating embryonal stem cells are a rich source of haemopoietic gene products and suggest erythroid preconditioning of primitive haemopoietic stem cells. J Biol Chem, 276(12), eScholarID:1d3843
  • Hampson L, El Hady ES, Moore JV, Kitchener HC, Hampson IN. (2001). The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. Faseb Journal, 15(8), eScholarID:1d3848 | DOI:10.1096/fj.00-0728fje
  • Hampson L, Hampson IN, Babichuk CK, Cotter L, Bleackley RC, Dexter TM, Cross MA. (2001). A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells. Hematol J, 2(3), eScholarID:1d3851

2000

  • Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. (2000). CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J, 14(1), eScholarID:1d3835
  • McIvor ZJ, Heyworth CM, Johnson BA, Pearson S, Fiegler H, Hampson L, Dexter TM, Cross MA. (2000). A transient assay for regulatory gene function in haemopoietic progenitor cells. Br J Haematol, 110(3), 674-681. eScholarID:35055

1999

  • Sugimoto, M, Nakamura, T, Ohtani, N, Hampson, L, Hampson, IN, Shimamoto, A, Furuichi, Y, Okumura, K, Niwa, S, Taya, Y, Hara, E. (1999). Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev, 13(22), eScholarID:1d3829

Top of page

| Skip to main content | Skip to navigation | Skip to Search |